

Patient details

Date of birth (dd-mm-yyyy) _____

Surname and initials _____

Gender _____

Address _____

ZIP / postal code _____

City _____

Country _____

Your reference _____

Send form with sample to:

Sanquin Diagnostics
 Department: UDC
 Plesmanlaan 125
 1066 CX Amsterdam
 the Netherlands

Client

Clinician _____

Institute _____

Department _____

Address or PO box _____

ZIP / postal code _____

City _____

Country _____

Send invoice to (if different from client)

Institute _____

Department _____

Address or PO box _____

ZIP / postal code _____

City _____

Country _____

E-mail address _____

Blood samples (for serum preparation) should be drawn shortly before administration of the drug.

• 1 ml serum

Sample date (dd-mm-yyyy) _____

Date of last administration _____

Dosage _____

Drug	Concentration of drug in serum	IgG (total) against drug	First concentration of drug, followed by IgG measurement if concentration is low
Abatacept (Orencia)	<input type="checkbox"/> J301 concentration	_____	_____
Adalimumab (Humira)	<input type="checkbox"/> J291 concentration	<input type="checkbox"/> J290 IgG (total) against	<input type="checkbox"/> J283 cascade
Certolizumab (Cimzia)	<input type="checkbox"/> J304 concentration	<input type="checkbox"/> J303 IgG (total) against	_____
Etanercept (Enbrel)	<input type="checkbox"/> J295 concentration	_____	_____
Golimumab (Simponi)	<input type="checkbox"/> J306 concentration	<input type="checkbox"/> J305 IgG (total) against	_____
Infliximab <input type="checkbox"/> Remicade / <input type="checkbox"/> Inflectra / <input type="checkbox"/> Remsima	<input type="checkbox"/> J289 concentration	<input type="checkbox"/> J288 IgG (total) against	<input type="checkbox"/> J285 cascade
Natalizumab (Tysabri)	<input type="checkbox"/> J299 concentration	<input type="checkbox"/> J307 IgG (total) against	_____
Omalizumab (Xolair)	<input type="checkbox"/> J309 concentration	<input type="checkbox"/> J308 IgG (total) against	_____
Rituximab (Mabthera)	<input type="checkbox"/> J293 concentration	<input type="checkbox"/> J292 IgG (total) against	_____
Tocilizumab (Actemra)	<input type="checkbox"/> J311 concentration	<input type="checkbox"/> J310 IgG (total) against	_____
Trastuzumab (Herceptin)	<input type="checkbox"/> J298 concentration	<input type="checkbox"/> J312 IgG (total) against	_____
Ustekinumab (Stelara)	<input type="checkbox"/> J134 concentration	<input type="checkbox"/> J133 IgG (total) against	_____
Other biologicals	<input type="checkbox"/> J297 concentration	<input type="checkbox"/> J296 IgG (total) against	_____

Not all assays mentioned above have been completely validated.

Current validation status can be found on our website <http://www.sanquin.nl/en/products-services/biologicals/available-assays/>

Usage of residual material for additional research

In a small number of cases, remnants of patient material can be used for validation, equipment calibration and scientific research, after being rendered anonymous. Should the patient have objections to this, or if you have indications that the patient could have objections, please contact the management of Sanquin Diagnostic Services at any moment at +31 20 512 3470/3479 or by e-mail to diagnostic.services@sanquin.nl.



Serum submission

Send form with
 1 ml frozen serum
 sample to:
 Sanquin Diagnostic
 Services
 Dept. UDC
 Plesmanlaan 125
 1066 CX Amsterdam
 The Netherlands



Sanquin

+31 20 512 3449
biologicals@sanquin.nl